Joshua I. Rothman focuses on patent and trade secret law in the pharmaceutical, biotechnology, and medical device arenas. Josh litigates complex cases for both the patentee and accused infringer. He also counsels clients on mergers and acquisitions due diligence, licensing, and other transactional matters.
He has significant experience litigating Hatch-Waxman cases, from pre-lawsuit through appeal, involving blockbuster drugs, such as Prilosec®, Accupril®, Imitrex®, Benicar®, and Sensipar®, including patents covering chemical compounds, polymorphs, enantiomers, salt and solvate forms, solid and sterile formulations, and methods of use and treatment.
- Represented Bristol-Myers Squibb in Lek v. Bristol-Myers Squibb and Watson Laboratories (lipid-lowering pharmaceuticals)
- Represented GlaxoSmithKline in In Re 845 Patent Litigation, GlaxoSmithKline v. Dr. Reddy’s, GlaxoSmithKline v. Cobalt Pharmaceuticals and GlaxoSmithKline v. Spectrum Pharmaceuticals (anti-migraine pharmaceuticals)
- Represented AstraZeneca in In Re Omeprazole Patent Litigation, AstraZeneca vs. Andrx, AstraZeneca v. GenPharm, AstraZeneca v. Dr. Reddy’s, and AstraZeneca v. Kremer Urban Development Company (proton pump inhibitor pharmaceuticals)
- Represented Brigham and Women’s Hospital, and Amgen Inc., in Brigham and Women’s Hospital, et al. v. Barr and Teva (calcium receptor modulating pharmaceuticals).
- J.D. Brooklyn Law School 1998
- M.S. Rensselaer Polytechnic Institute 1994
- B.S. University of Michigan 1993
Bar Admissions : New York State 1999
Court Admissions :
- U.S. District Court for the Southern District of New York
- U.S. District Court for the Eastern District of New York
- U.S. Court of Appeals for the Federal Circuit
- U.S. Supreme Court 2011
Community : Active in the firm’s pro bono practice and has helped clients obtain Section 8 housing, U-visas, and disability benefits.
Rate : $$$$